Grant ID RP180771
Awarded On August 24, 2018
Title Small Molecule for Selective Targeting of Epithelial-Mesenchymal Transition-Induced Cancer Stem Cells
Program Academic Research
Award Mechanism High Impact/High Risk
Institution/Organization Baylor University
Principal Investigator/Program Director Joe Taube
Cancer Sites Breast
Contracted Amount $199,951
Lay Summary

Nearly half of triple-negative breast cancer (TNBC) patients fail to respond to chemotherapy and suffer median survival rates fewer than 3 years. While hormone- and growth factor receptor-targeted drug treatments have improved outcomes for other subtypes of breast cancer, patients with TNBC face limited options and eventually succumb to either primary tumor recurrence or distant metastases. For TNBC patients with brain metastases median overall survival is less than 5 months. Tumors are composed of a mixture of distinct cell sub-types which unequally drive progression and response to treatment. Cancer stem cells (CSCs) are often present as a subpopulation of most breast cancers and are resp...

Read More